Home > Healthcare > Pharmaceuticals > Finished Drug Form > Polycystic Ovarian Syndrome Treatment Market

Polycystic Ovarian Syndrome Treatment Market Share

Report ID: GMI9770
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Polycystic Ovarian Syndrome Treatment Market Share

The competitive landscape of the polycystic ovarian syndrome (PCOS) treatment market is characterized by a mix of pharmaceutical companies, biotech firms, and healthcare providers offering a range of treatment options. Major players in the market include pharmaceutical giants like Bayer AG, Merck & Co., Inc., and Pfizer Inc., which offer medications such as oral contraceptives, anti-androgens, and insulin-sensitizing agents. Overall, the PCOS treatment market is highly competitive, with companies constantly innovating to meet the growing demand for effective and safe treatment options.

Polycystic Ovarian Syndrome Treatment Market Companies

Prominent players operating in the industry include:

Abbott Laboratories
AbbVie Plc
Addex Therapeutics Ltd.
AstraZeneca PLC
Bayer AG
Bristol-Myer Squibb Company
Ferring BV
Johnson and Johnson
Merck KGaA
Mylan N.V
Novartis AG
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global polycystic ovarian syndrome treatment industry was valued at USD 5.6 billion in 2023 and is anticipated to register 5.8% CAGR between 2024 and 2032 due to rising awareness and diagnosis along with higher incidence of obesity and sedentary lifestyle.

The polycystic ovarian syndrome (PCOS) treatment market size from insulin-sensitizing agents segment accounted for USD 1.3 billion, driven by the widespread recognition of insulin resistance and increasing awareness among healthcare providers and patients.

North America market size is anticipated to reach USD 3.5 billion by 2032 due to the high prevalence of PCOS, robust healthcare infrastructure and widespread access to advanced medical technologies.

Abbott Laboratories, AbbVie Plc, Addex Therapeutics Ltd., AstraZeneca PLC, Bayer AG, Bristol-Myer Squibb Company, Ferring BV, Johnson and Johnson, Merck KGaA, Mylan N.V, Novartis AG, and Pfizer Inc. among others.